Evidence map›Paper›PMID 29262732›Full record

ArticleCell cycle (Georgetown, Tex.)2018

Chk1 modulates the interaction between myosin phosphatase targeting protein 1 (MYPT1) and protein phosphatase 1cβ (PP1cβ).

Xiaomei Hu, Zhe Li, Yuehe Ding, Qizhi Geng, Zhikai Xiahou, Huanwei Ru, Meng-Qiu Dong, Xingzhi Xu, Jing Li

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Journal of biological chemistry · 2020
    Article
  6. Regulation of cardiac O-GlcNAcylation: More than just nutrient availability.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiaomei Hua Beijing Key Laboratory of DNA Damage Response and College of Life Sciences , Capital Normal University , Beijing 100048 , China.
Zhe Lia Beijing Key Laboratory of DNA Damage Response and College of Life Sciences , Capital Normal University , Beijing 100048 , China.ORCID 0000-0002-6211-8990
Yuehe Dingb National Institute of Biological Sciences , Beijing 102206 , China.
Qizhi Genga Beijing Key Laboratory of DNA Damage Response and College of Life Sciences , Capital Normal University , Beijing 100048 , China.
Zhikai Xiahoua Beijing Key Laboratory of DNA Damage Response and College of Life Sciences , Capital Normal University , Beijing 100048 , China.
Huanwei Rua Beijing Key Laboratory of DNA Damage Response and College of Life Sciences , Capital Normal University , Beijing 100048 , China.
Meng-Qiu Dongb National Institute of Biological Sciences , Beijing 102206 , China.
Xingzhi Xua Beijing Key Laboratory of DNA Damage Response and College of Life Sciences , Capital Normal University , Beijing 100048 , China.
Jing Lia Beijing Key Laboratory of DNA Damage Response and College of Life Sciences , Capital Normal University , Beijing 100048 , China.ORCID 0000-0002-3977-1641
Capital Normal University · CNNational Institute of Biological Sciences, Beijing · CNShenzhen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polo-like kinase 1 (Plk1) is an instrumental kinase that modulates many aspects of the cell cycle. Previous investigations have indicated that Plk1 is a target of the DNA damage response, and Plk1 inhibition is dependent on ATM/ATR and Chk1. But the exact mechanism remains elusive. In a proteomic screen to identify Chk1-interacting proteins, we found that myosin phosphatase targeting protein 1 (MYPT1) was present in the immunocomplex. MYPT1 is phosphorylated by CDK1, thus recruiting protein phosphatase 1β (PP1cβ) to dephosphorylate and inactivate Plk1. Here we identified that Chk1 directly interacts with MYPT1 and preferentially phosphorylates MYPT1 at Ser20, which is essential for MYPT1-PP1cβ interaction and subsequent Plk1 dephosphorylation. Phosphorylation of Ser20 is abolished during mitotic damage when Chk1 is inhibited. The degradation of MYPT1 is also regulated by Chk1 phosphorylation. Our results thus unveil the underlying machinery that attenuates Plk1 activity during mitotic damage through Chk1-induced phosphorylation of MYPT1.

Indexed as

Amino Acid SequenceAnimalsAtaxia Telangiectasia Mutated ProteinsCDC2 Protein KinaseCell Cycle ProteinsHEK293 CellsHeLa CellsHumansMitosisMyosin-Light-Chain PhosphatasePhosphopeptidesPhosphorylationPolo-Like Kinase 1Protein BindingProtein Phosphatase 1Protein Serine-Threonine KinasesAtaxia Telangiectasia Mutated ProteinsCDC2 Protein KinaseCell Cycle ProteinsMyosin-Light-Chain PhosphatasePhosphopeptidesPolo-Like Kinase 1PPP1R12A protein, humanProtein Phosphatase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsSerineCell cycleDNA damagemitosisMYPT1Plk1PP1cβ

Identifiers

PMID29262732
PMCPMC5927650
OpenAlexW2776463716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.